BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 11516938)

  • 1. Multi-resistance to antimicrobial agents for the ten most frequently isolated bacterial pathogens.
    Fluit AC; Schmitz FJ; Verhoef J;
    Int J Antimicrob Agents; 2001 Aug; 18(2):147-60. PubMed ID: 11516938
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998.
    Fluit AC; Verhoef J; Schmitz FJ;
    Eur J Clin Microbiol Infect Dis; 2001 Sep; 20(9):617-25. PubMed ID: 11714042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
    Zhanel GG; DeCorby M; Laing N; Weshnoweski B; Vashisht R; Tailor F; Nichol KA; Wierzbowski A; Baudry PJ; Karlowsky JA; Lagacé-Wiens P; Walkty A; McCracken M; Mulvey MR; Johnson J; ; Hoban DJ
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1430-7. PubMed ID: 18285482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
    Hsueh PR; Huang WK; Shyr JM; Lau YJ; Liu YC; Luh KT
    J Formos Med Assoc; 2004 Sep; 103(9):664-70. PubMed ID: 15361938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
    Pontani D; Washton H; Bouchillon S; Johnson J
    Eur J Clin Microbiol Infect Dis; 1998 Jun; 17(6):413-9. PubMed ID: 9758284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Susceptibilities of bacteria isolated from patients with lower respiratory infectious diseases to antibiotics (1997)].
    Ikemoto H; Ito C; Yoshida T; Watanabe K; Mori T; Ohno I; Okada S; Igari J; Arakawa M; Igarashi K; Oguri T; Okada M; Ozaki K; Terai T; Aoki N; Inoue H; Nakadate T; Kitamura N; Sekine O; Suzuki Y; Ando M; Suga M; Sato K; Nakata K; Kusano N
    Jpn J Antibiot; 1999 May; 52(5):353-97. PubMed ID: 10480048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.
    Vega S; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2017 Jul; 16(1):50. PubMed ID: 28701170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of the pathogenic characteristics of 162 severely burned patients with bloodstream infection].
    Gong YL; Yang ZC; Yin SP; Liu MX; Zhang C; Luo XQ; Peng YZ
    Zhonghua Shao Shang Za Zhi; 2016 Sep; 32(9):529-35. PubMed ID: 27647068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteriologic profile and antibiogram of blood culture isolates from a children's hospital in Kabul.
    Tariq TM
    J Coll Physicians Surg Pak; 2014 Jun; 24(6):396-399. PubMed ID: 24953929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.
    Morfin-Otero R; Noriega ER; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2015 Dec; 14():53. PubMed ID: 26667651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of distribution and drug resistance of pathogens from the wounds of 1 310 thermal burn patients].
    Zhang C; Gong YL; Luo XQ; Liu MX; Peng YZ
    Zhonghua Shao Shang Za Zhi; 2018 Nov; 34(11):802-808. PubMed ID: 30481922
    [No Abstract]   [Full Text] [Related]  

  • 14. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia.
    Fritsche TR; Sader HS; Stilwell MG; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):187-93. PubMed ID: 16105563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative in vitro activity of gemifloxacin, ciprofloxacin, levofloxacin and ofloxacin in a North American surveillance study.
    Hoban DJ; Bouchillon SK; Johnson JL; Zhanel GG; Butler DL; Miller LA; Poupard JA;
    Diagn Microbiol Infect Dis; 2001; 40(1-2):51-7. PubMed ID: 11448564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000: results from The Surveillance Network (TSN) Database-USA.
    Karlowsky JA; Jones ME; Mayfield DC; Thornsberry C; Sahm DF
    Int J Antimicrob Agents; 2002 May; 19(5):413-26. PubMed ID: 12007850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nationwide surveillance of parenteral antibiotics containing meropenem activities against clinically isolated strains in 2006].
    Yamaguchi K; Ishii Y; Iwata M; Watanabe N; Uehara N; Yasujima M; Kasai T; Suwabe A; Yamahata K; Kaku M; Kanemitsu K; Imafuku Y; Nishiyama K; Murakami M; Yomoda S; Taniguchi N; Yamada T; Nomura F; Watanabe M; Kanno H; Aihara M; Maesaki S; Hashikita G; Kondo S; Misawa S; Horiuchi H; Tazawa Y; Nakashima H; Takemura H; Okada M; Yamazaki F; Horii T; Maekawa M; Baba H; Ishigo S; Fujita N; Komori T; Ichiyama S; Iinuma Y; Maeda S; Yamanaka K; Murata Y; Matsuo S; Kohno H; Kinoshita S; Fujita J; Negayama K; Murase M; Miyamoto H; Kusano N; Mihara E; Itaha H; Ono J; Yoshimura H; Yanagihara K; Matsuda J; Saikawa T; Hiramatsu K
    Jpn J Antibiot; 2007 Dec; 60(6):344-77. PubMed ID: 18447206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo antibacterial activities of SM-216601, a new broad-spectrum parenteral carbapenem.
    Ueda Y; Kanazawa K; Eguchi K; Takemoto K; Eriguchi Y; Sunagawa M
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4185-96. PubMed ID: 16189097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004).
    Watters AA; Jones RN; Leeds JA; Denys G; Sader HS; Fritsche TR
    J Antimicrob Chemother; 2006 May; 57(5):914-23. PubMed ID: 16549511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study.
    Walkty A; Adam HJ; Laverdière M; Karlowsky JA; Hoban DJ; Zhanel GG;
    Diagn Microbiol Infect Dis; 2011 Mar; 69(3):348-55. PubMed ID: 21353964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.